The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
Open accessAbstract
Local chemotherapy synergizes with immunotherapy against glioblastoma, whereas systemic chemotherapy abrogates its antitumor effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationStupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Zeng, J., See, A. P., Phallen, J., Jackson, C. M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T. J., Albesiano, E., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.025 · Cited by 889
Self-citationImmunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
Grossman, S. A., Ye, X., Lesser, G., Sloan, A., Carraway, H., Desideri, S., & Piantadosi, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0774 · Cited by 578
Self-citationDEPRESSED CELL-MEDIATED IMMUNITY IN PATIENTS WITH PRIMARY INTRACRANIAL TUMORS
Brooks, W. H., Netsky, M. G., Normansell, D. E., & Horwitz, D. A. (1972) · The Journal of Experimental Medicine · doi:10.1084/jem.136.6.1631 · Cited by 368
Pharmacokinetics of the Carmustine Implant
Fleming, A. B., & Saltzman, W. M. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241060-00002 · Cited by 287
Tamargo, R. J., Myseros, J. S., Epstein, J. I., Yang, M. B., Chasin, M., & Brem, H. (1993) · PubMed · Cited by 247
Self-citationRegulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective
Le, D. T., & Jaffee, E. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3912 · Cited by 240
Nivolumab: Targeting PD-1 to Bolster Antitumor Immunity
Brahmer, J. R., Hammers, H., & Lipson, E. J. (2015) · Future Oncology · doi:10.2217/fon.15.52 · Cited by 199
Affronti, M. L., Heery, C. R., Herndon, J. E., Rich, J. N., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Friedman, A. H., Bigner, D. D., & Friedman, H. S. (2009) · Cancer · doi:10.1002/cncr.24398 · Cited by 138
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors
Reithmeier, T., Graf, E., Piroth, T., Trippel, M., Pinsker, M. O., & Nikkhah, G. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-30 · Cited by 107
Preynat‐Seauve, O., Schuler, P., Contassot, E., Beermann, F., Huard, B., & French, L. E. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.61 · Cited by 100
Profound Impairment of Adaptive Immune Responses by Alkylating Chemotherapy
Litterman, A. J., Zellmer, D. M., Grinnen, K. L., Hunt, M. A., Dudek, A. Z., Salazar, A. Μ., & Ohlfest, J. R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203539 · Cited by 71
Ohlfest, J. R., Andersen, B. M., Litterman, A. J., Xia, J., Pennell, C. A., Swier, L. E., Salazar, A. Μ., & Olin, M. R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201557 · Cited by 55
Vaccine Strategies for Glioblastoma: Progress and Future Directions
Jackson, C. M., Ruzevick, J., Brem, H., & Lim, M. K. (2013) · Immunotherapy · doi:10.2217/imt.12.155 · Cited by 35
Self-citationCombining immunotherapy with chemotherapy to treat cancer.
van der Most, R., Robinson, B. W. S., & Lake, R. (2005) · UWA Profiles and Research Repository (UWA) · Cited by 35
Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination
Hailemichael, Y., & Overwijk, W. W. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.04.019 · Cited by 22
Litterman, A. J., Dudek, A. Z., & Largaespada, D. A. (2013) · OncoImmunology · doi:10.4161/onci.26294 · Cited by 22
Cited by
The Microenvironmental Landscape of Brain Tumors
Quail, D. F., & Joyce, J. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.009 · Cited by 1,862
Hiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Self-citationWen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citationMechanisms of immunotherapy resistance: lessons from glioblastoma
Jackson, C. M., Choi, J., & Lim, M. (2019) · Nature Immunology · doi:10.1038/s41590-019-0433-y · Cited by 751
Self-citation
Metadata
- Authors
- Mathios, D., Kim, J. E., Mangraviti, A., Phallen, J., Park, C.-K., Jackson, C. M., Garzon-Muvdi, T., Kim, E., Theodros, D., Polanczyk, M., Martin, A. M., Suk, I., Ye, X., Tyler, B., Bettegowda, C., Brem, H., Pardoll, D. M., & Lim, M.
- Venue
- Science Translational Medicine
- Published
- 2016-12-21
- Volume
- 8
- Issue
- 370
- Pages
- 370ra180-370ra180
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2563647161
- Cited by
- 296
- References
- 20
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.